Analysis of TCGA datasets showed that ovarian cancer patients with higher GOLPH3L expression had a shorter survival time and demonstrated an earlier relapse disease-free survival time (P < 0.05; Fig. 1c). The gene discussed is GOLPH3L; the disease is ovarian cancer.